Phagelux Announces Acquisition of Omnilytics

SHANGHAI and MONTREAL and SALT LAKE CITY, UT, July 20, 2015 /PRNewswire/ - Phagelux, Inc., a leading anti-bacterial company, is pleased to announce the purchase of OmniLytics, Inc., headquartered in Salt Lake City, a pioneer in the research and development of bacteriophage solutions for pathogen control in the fields of agriculture, food and water safety, and sanitation.    

OmniLytics has several category leading products including a line of treatments for bacterial diseases in agriculture, which are marketed under the AgriPhage brand as well as several food safety products sold by partners under their respective brands.

Mark Engel, Chairman of Phagelux, says "we are extremely excited to have the OmniLytics team join our organization. They bring with them great science, first-class product development capabilities, and US manufacturing presence." Mr. Engel adds that "there is also great synergy between the OmniLytics products and our own AgriHealth lines." 

Mr. Justin Reber, Chairman of OmniLytics, emphasized that our shareholders "are very excited to be a part of the Phagelux business. We believe that combining Phagelux's capabilities and access to the broader international markets with OmniLytics experience and commercial operations in the U.S. will provide the synergies necessary to rapidly expand both companies' bacteriophage products globally."

About Phagelux, Inc.

Phagelux, Inc. is developing anti-bacterial solutions across multiple fields utilizing various phage and phage-based technologies and solutions.  Phagelux is headquartered in Shanghai with laboratories in China and North America and a factory under construction in China. Phagelux has both HumanHealth and AgriHealth divisions.